Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study - Concepedia

Concepedia

Publication | Open Access

Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study

DOI Full Paper Access

108

Citations

16

References

2021

Year

Margaret A. Tempero, Do‐Youn Oh, Josep Tabernero, Michele Reni, Eric Van Cutsem, Andrew Hendifar, Dirk Waldschmidt, Naureen Starling, Jean‐Baptiste Bachet, Heung Moon Chang,

Annals of Oncology

Abstract

Ibrutinib plus nab-paclitaxel/gemcitabine did not improve OS or PFS for patients with PDAC. Safety was consistent with known profiles for these agents.

References

	Year	Citations

Page 1